Clinical Trials
12 trialsNCT07609862 2026-05-27
A Phase Ib/II Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 1/2 Not yet recruiting
NCT07592481 2026-05-22
HEMO-CONNECT
Centre Hospitalier de la côte Basque
Phase NA Not yet recruiting
NCT07101328 2026-05-13
BAF_FRontier-1
Eli Lilly and Company
Phase 1 Not yet recruiting
NCT07548450 2026-04-23
MPOWER
University of Utah
Phase 2 Not yet recruiting
NCT07474961 2026-03-16
BLOOD-dose
Rigshospitalet, Denmark
Phase 4 Not yet recruiting
NCT07464210 2026-03-11
Nemtabrutinib, Bortezomib, and Rituximab for WM
Seoul National University Hospital
Phase 2 Not yet recruiting
NCT07426484 2026-02-23
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Dana-Farber Cancer Institute
Phase 4 Not yet recruiting
NCT07424833 2026-02-20
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Ascentage Pharma Group Inc.
Phase 1 Not yet recruiting
NCT07420959 2026-02-19
ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia
Mayo Clinic
Phase 1/2 Not yet recruiting
NCT07259122 2025-12-02
ZBR in WM
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Not yet recruiting
NCT06547866 2025-11-26
WAZABI
French Innovative Leukemia Organisation
Phase 2 Not yet recruiting
NCT07169565 2025-09-11
Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Not yet recruiting